Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kyntra Bio (KYNB) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $6.5 million.

  • Kyntra Bio's Operating Expenses fell 8643.31% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.8 million, marking a year-over-year decrease of 7497.4%. This contributed to the annual value of $180.0 million for FY2024, which is 5127.87% down from last year.
  • As of Q3 2025, Kyntra Bio's Operating Expenses stood at $6.5 million, which was down 8643.31% from $13.4 million recorded in Q2 2025.
  • Over the past 5 years, Kyntra Bio's Operating Expenses peaked at $158.2 million during Q2 2021, and registered a low of $6.5 million during Q3 2025.
  • For the 5-year period, Kyntra Bio's Operating Expenses averaged around $81.7 million, with its median value being $103.6 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 79727.4% in 2021, then crashed by 8643.31% in 2025.
  • Quarter analysis of 5 years shows Kyntra Bio's Operating Expenses stood at $151.8 million in 2021, then tumbled by 33.77% to $100.5 million in 2022, then tumbled by 78.82% to $21.3 million in 2023, then crashed by 51.77% to $10.3 million in 2024, then crashed by 36.82% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, $13.4 million for Q2 2025, and $17.7 million during Q1 2025.